Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Nurexone Biologic: Jetzt diese wirklich einzigartige Chance ergreifen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Business Wire-Archiv vom 22.10.2023

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
22.10.23Natera, Inc.: Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera's Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients518Builds on published evidence with twice as many patients and disease-free survival data extended to 24 months Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced...
► Artikel lesen
22.10.23Agenus Inc.: Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma684U.S. BLA Filing in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (CRC) Planned for Midyear 2024 Potential Accelerated Filings for Advanced Pancreatic Cancer and Melanoma in 2025 Opportunity...
► Artikel lesen
22.10.23Genmab A/S: TIVDAK (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial598TIVDAK demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023...
► Artikel lesen
22.10.23Seagen Inc.: TIVDAK (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial546TIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented at ESMO 2023 congress Results...
► Artikel lesen